DOCKET NO.: 1702.401900 (60283-USA; FMC-1213) PATENT APPLICATION

SERIAL NO.: 09/763,682 FILED: APRIL 27, 2001

B(3)

comprises an immunoisolating alginate having a G content of above 15%, wherein the molecule is a molecule that is capable of interacting with tumor/host communication pathways, wherein the CNS tumor is a brain tumor.

B B

21 (Amended). A composition comprising a producer cell that expresses a molecule that is an inhibitor of the growth of a CNS tumor, the cell being encapsulated in a matrix that comprises an immunoisolating alginate having a G content of above 15%, wherein the molecule is a molecule that is capable of interacting with tumor/host communication pathways, wherein the producer cell is encapsulated in a bead or microbead and the alginate concentration within the bead or microbead increases from the center of the bead or the microbead to the outer rim.

29 (New). The method according to claim 27 wherein the molecule that is capable of interacting with tumor/host communication pathways is a molecule capable of affecting tumor neovascularization selected from the group consisting of: thrombospondin, endostatin, angiostatin, and prolactin.

Juh J

30 (New). The method according to claim 27 wherein the wherein the producer cell is encapsulated in a bead or microbead and the alginate concentration within the bead or microbead increases from the center of the bead or the microbead to the outer rim.

31 (New). The composition according to claim 22 wherein the molecule that is capable of affecting tumor neovascularization is selected from the group consisting of: thrombospondin, endostatin, angiostatin, and prolactin.

50B/

32 (New). The composition according to claim 12 wherein the producer cell comprises a plasmid that includes a nucleic acid sequence that encodes a protein that is capable of